Alnylam Pharmaceutical sues Pfizer and Moderna over alleged patent infringement
Alnylam Pharmaceuticals Inc is suing Pfizer Inc and Moderna Inc for allegedly infringing its patent rights in lipid nanoparticle (LNP) technology used in their COVID-19 vaccines.
In Delaware Federal Court, the Biotech company, Alnylam Pharmaceuticals, took legal action against two pharmaceutical industries, Pfizer and Moderna. This is the third time Alnylam has sued Pfizer and Moderna in Delaware for allegedly violating its patent rights in LNP technology. Alnylam is seeking an unspecified share of royalties from the companies’ vaccine sales. It claims that Pfizer and Moderna allegedly infringed its patent rights in lipid nanoparticle (LNP) technology used in their COVID-19 vaccines. Pfizer earned $37.8 billion from sales of its Comirnaty vaccine last year, while Moderna made $18.4 billion from its Spikevax vaccine. Both companies have denied the allegations in the earlier cases and argued that Alnylam’s patents are invalid. Alnylam argued before the Delaware Federal Court that its LNP technology is essential to the mRNA-based vaccines and that the company shared confidential information with Moderna about the technology in 2014 for potential collaboration.